文献速递浆细胞疾病造血干细胞移植与细胞治疗

cilta-cel快速峰值扩增与多发性骨髓瘤迟发性神经毒性相关

Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma.
PubMed 文献 · Blood · 2026-01-01

研究采用统一流式平台评估90例R/R MM患者CAR T细胞动力学,cilta-cel扩增高于ide-cel;cilta-cel快速过度扩增与迟发性神经毒性(DNT)风险增加相关,峰值ALC可作替代标志物,并定义预测阈值。

要点

  • cilta-cel的CAR T细胞扩增中位数106个/μL,高于ide-cel的49个/μL。
  • cilta-cel中快速过度扩增与DNT风险增加相关,峰值中位数1009 vs 96个/μL。
  • 峰值ALC≥3×10³/μL或翻倍后≥2.5×10³/μL预测DNT风险,敏感性81%、特异性59%。

核心结论

  • cilta-cel与ide-cel的扩增-毒性关系不同,cilta-cel快速过度扩增与DNT风险增加相关。
  • 峰值ALC可作为CAR T细胞扩增的实用替代标志物,并定义预测DNT的定量阈值。

研究设计与样本

  • 采用统一流式细胞术平台评估CAR T细胞动力学的队列研究,N=90(cilta-cel n=54,ide-cel n=36)。
  • 多中心队列分析ALC作为替代标志物,N=532(cilta-cel n=256,ide-cel n=276)。

主要发现

  • cilta-cel的CAR T细胞扩增高于ide-cel(中位数106 vs 49个/μL)。
  • 峰值CAR T细胞扩增与ide-cel队列临床反应相关,但与cilta-cel队列无关。
  • cilta-cel中快速过度扩增与DNT风险增加相关(峰值中位数1009 vs 96个/μL)。
  • 较高峰值ALC与DNT发生显著相关,尤其是cilta-cel后的帕金森综合征。

关键数值与推荐

  • 峰值ALC≥3×10³/μL或翻倍后≥2.5×10³/μL预测DNT风险升高,敏感性81%、特异性59%。

临床怎么用

  • 可用峰值ALC早期识别cilta-cel治疗后DNT高风险患者,以制定预防策略减少疾病负担。

局限性

  • 原文未报告标准化CAR T细胞定量检测的可及性限制对研究的影响程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The impact of chimeric antigen receptor (CAR) T-cell expansion and persistence on clinical outcomes and treatment-related morbidity in patients with relapsed/refractory (R/R) multiple myeloma (MM) remains undefined, partly due to limited availability of standardized CAR T-cell quantification assays. We evaluated CAR T-cell kinetics and their association with efficacy and toxicity in patients with R/R MM treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel). Using a uniform flow cytometry-based platform (N = 90; cilta-cel, n = 54; ide-cel, n = 36), we observed greater CAR T-cell expansion with cilta-cel than with ide-cel (median, 106 vs 49 cells per μL). Peak CAR T-cell expansion was associated with clinical response in the ide-cel cohort but not in the cilta-cel cohort, in which rapid and excessive expansion was associated with an increased risk of delayed neurotoxicities (DNTs), a complication with potential long-term functional consequences (median peak, 1009 vs 96 cells per μL). To identify clinically accessible biomarkers of CAR T-cell expansion, we analyzed absolute lymphocyte count (ALC) as a surrogate biomarker in a multicenter cohort (N = 532; cilta-cel, n = 256; ide-cel, n = 276). Higher peak ALC was significantly associated with the development of DNTs, particularly parkinsonism after cilta-cel. A peak ALC ≥3 × 10³/μL, or ≥2.5 × 10³/μL following an increase of twofold or more, predicted elevated DNT risk (sensitivity, 81%; specificity, 59%). Together, these findings delineate distinct expansion-toxicity relationships in cilta-cel and ide-cel therapy, establish ALC as a practical, uniformly available surrogate for CAR T-cell expansion, and define quantitative thresholds that may enable early recognition of patients at risk of DNT, informing preemptive strategies to mitigate morbidity after cilta-cel.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hosoya H, Velayati A, Dima D, et al. Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma. Blood. 2026. PMID: 42418682. doi:10.1182/blood.2025032844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。